---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044974"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:01:51.100248+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q3: EsoGuard rev $1.2M (+50% YoY), net loss $12.4M ($0.25/share), raises $21.75M via notes

## Summary
- EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
- GAAP net loss attributable to common stockholders $12.4M, or $(0.25) per share.
- Non-GAAP adjusted loss $10.1M, or $(0.20) per share, excluding stock-based comp and other non-cash items.
- Cash $14.5M at Sep 30, 2024; entered into $21.75M senior secured convertible notes to extend cash runway.
- Performed 2,787 commercial EsoGuard tests in Q3; October record >1,400 tests; clinical validation study accepted.

## SEC filing metadata
- accession: 0001493152-24-044974
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315224044974/0001493152-24-044974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315224044974/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044974
- JSON: https://secwatch.observer/filing/0001493152-24-044974.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.